VANCOUVER, BC, Dec. 9, 2024 /PRNewswire/ — WAT Medical Enterprise proudly sponsored the 2024 Scottsdale Headache Symposium, organized by the American Headache Society from November 14-17 in Scottsdale, AZ. This annual event brought together a multidisciplinary audience of neurologists, general practitioners, pediatricians, anesthesiologists, psychologists, and other healthcare providers. The symposium featured diverse educational formats, including lectures, case studies, panel discussions, and hands-on demonstrations, offering cutting-edge insights into headache diagnosis and treatment.
One of the highlights of the event was the HeadaTerm 2, a newly developed neuromodulation device that garnered significant attention for its innovative design, ease of use, and competitive pricing. HeadaTerm 2 utilizes external trigeminal nerve stimulation and is FDA-cleared for the preventive treatment of migraines. Clinical studies indicate that it can be up to 35% more effective than oral NSAIDs in managing acute migraine episodes, underscoring its potential to transform headache care.
Additionally, WAT Medical showcased EmeTerm, an FDA-cleared anti-nausea wristband designed to alleviate nausea and vomiting often associated with migraines. The drug-free wristband, highly rated by consumers and clinicians, is a top-selling product on Amazon and widely endorsed by medical professionals across North America.
By collaborating with influential organizations such as the American Headache Society and the American Migraine Foundation, WAT Medical continues its commitment to advancing migraine treatment through groundbreaking neuromodulation technologies, aiming to enhance patient outcomes and improve quality of life.
References:
[1]Hokenek N M, Erdogan M O, Hokenek U D, et al. Treatment of migraine attacks by transcutaneous electrical nerve stimulation in emergency department: A randomize controlled trial[J]. The American Journal of Emergency Medicine, 2021, 39: 80-85.
[2]www.americanheadachesociety.org
[3]www.watmedical.com
[4]www.emeterm.com
ข่าวที่เกี่ยวข้อง
- World Young Scientist Summit 2026 Opens in Wenzhou, Zhejiang
- The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
- Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
- 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
